TISIDB

Summary
Symbol	FCGR1A
Name	Fc fragment of IgG, high affinity Ia, receptor (CD64)
Aliases	CD64; CD64A; Fc fragment of IgG, high affinity Ia, receptor for (CD64); FCRI; Fc gamma receptor; Fc-gamma RI ......
Chromosomal Location	1q21.2-q21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane Single-pass type I membrane protein Note=Stabilized at the cell membrane through interaction with FCER1G.
Domain	PF00047 Immunoglobulin domain PF13895 Immunoglobulin domain
Function	High affinity receptor for the Fc region of immunoglobulins gamma. Functions in both innate and adaptive immune responses.

> Gene Ontology [ TOP ]
Biological Process	GO:0002429 immune response-activating cell surface receptor signaling pathway GO:0002431 Fc receptor mediated stimulatory signaling pathway GO:0002433 immune response-regulating cell surface receptor signaling pathway involved in phagocytosis GO:0002474 antigen processing and presentation of peptide antigen via MHC class I GO:0002478 antigen processing and presentation of exogenous peptide antigen GO:0002479 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002757 immune response-activating signal transduction GO:0002764 immune response-regulating signaling pathway GO:0002768 immune response-regulating cell surface receptor signaling pathway GO:0006898 receptor-mediated endocytosis GO:0006909 phagocytosis GO:0006911 phagocytosis, engulfment GO:0010324 membrane invagination GO:0019882 antigen processing and presentation GO:0019884 antigen processing and presentation of exogenous antigen GO:0034341 response to interferon-gamma GO:0038093 Fc receptor signaling pathway GO:0038094 Fc-gamma receptor signaling pathway GO:0038096 Fc-gamma receptor signaling pathway involved in phagocytosis GO:0042590 antigen processing and presentation of exogenous peptide antigen via MHC class I GO:0048002 antigen processing and presentation of peptide antigen GO:0060333 interferon-gamma-mediated signaling pathway GO:0071346 cellular response to interferon-gamma GO:0099024 plasma membrane invagination
Molecular Function	GO:0005057 receptor signaling protein activity GO:0019864 IgG binding GO:0019865 immunoglobulin binding
Cellular Component	GO:0005769 early endosome GO:0010008 endosome membrane GO:0030135 coated vesicle GO:0030136 clathrin-coated vesicle GO:0030139 endocytic vesicle GO:0030659 cytoplasmic vesicle membrane GO:0030662 coated vesicle membrane GO:0030665 clathrin-coated vesicle membrane GO:0030666 endocytic vesicle membrane GO:0030669 clathrin-coated endocytic vesicle membrane GO:0031901 early endosome membrane GO:0044440 endosomal part GO:0045334 clathrin-coated endocytic vesicle

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04145 Phagosome hsa04380 Osteoclast differentiation hsa04640 Hematopoietic cell lineage hsa04666 Fc gamma R-mediated phagocytosis
Reactome	R-HSA-1280218: Adaptive Immune System R-HSA-1236975: Antigen processing-Cross presentation R-HSA-983169: Class I MHC mediated antigen processing & presentation R-HSA-1236978: Cross-presentation of soluble exogenous antigens (endosomes) R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-2029481: FCGR activation R-HSA-2029480: Fcgamma receptor (FCGR) dependent phagocytosis R-HSA-168256: Immune System R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell R-HSA-168249: Innate Immune System R-HSA-913531: Interferon Signaling R-HSA-877300: Interferon gamma signaling R-HSA-2029482: Regulation of actin dynamics for phagocytic cup formation R-HSA-2029485: Role of phospholipids in phagocytosis

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04145 Phagosome
hsa04380 Osteoclast differentiation
hsa04640 Hematopoietic cell lineage
hsa04666 Fc gamma R-mediated phagocytosis

Reactome

R-HSA-1280218: Adaptive Immune System
R-HSA-1236975: Antigen processing-Cross presentation
R-HSA-983169: Class I MHC mediated antigen processing & presentation
R-HSA-1236978: Cross-presentation of soluble exogenous antigens (endosomes)
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2029481: FCGR activation
R-HSA-2029480: Fcgamma receptor (FCGR) dependent phagocytosis
R-HSA-168256: Immune System
R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
R-HSA-168249: Innate Immune System
R-HSA-913531: Interferon Signaling
R-HSA-877300: Interferon gamma signaling
R-HSA-2029482: Regulation of actin dynamics for phagocytic cup formation
R-HSA-2029485: Role of phospholipids in phagocytosis

Summary
Symbol	FCGR1A
Name	Fc fragment of IgG, high affinity Ia, receptor (CD64)
Aliases	CD64; CD64A; Fc fragment of IgG, high affinity Ia, receptor for (CD64); FCRI; Fc gamma receptor; Fc-gamma RI ......
Chromosomal Location	1q21.2-q21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between FCGR1A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between FCGR1A and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
24523193	Chronic Myelomonocytic Leukemia; Acute Myelomonocytic Leukemia	Promote immunity	Here, we report the use of CD64 as a novel target for specific CMML and AMML therapy, and correlate CD64 expression with typical surface markers representing these diseases.
16452176	Melanoma	Promote immunity; increase the efficacy of immunotherapy	The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma. MPL did potently boost TA99 antibody-induced effects, and combination therapy was, again, found to be dependent on the presence of FcgammaRI.
29576376	Pancreatic Carcinoma	Promote immunity	Fc gamma receptor All mAb formats were strong agonists when hyper-crosslinked; however, only those binding the membrane-distal cysteine-rich domain 1 (CRD1) retained agonistic activity with physiological Fc gamma receptor crosslinking or as human immunoglobulin G2 isotype; agonistic activity decreased as epitopes drew closer to the membrane.
23293080	Melanoma	Promote immunity	The high-affinity human IgG receptor FcγRI (CD64) promotes IgG-mediated inflammation, anaphylaxis, and antitumor immunotherapy. Finally, hFcgammaRI was capable of mediating antibody-induced immunotherapy of metastatic melanoma. Our results unravel novel capabilities of human FcgammaRI that confirm the role of high-affinity IgG receptors in vivo.

Summary
Symbol	FCGR1A
Name	Fc fragment of IgG, high affinity Ia, receptor (CD64)
Aliases	CD64; CD64A; Fc fragment of IgG, high affinity Ia, receptor for (CD64); FCRI; Fc gamma receptor; Fc-gamma RI ......
Chromosomal Location	1q21.2-q21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of FCGR1A in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	FCGR1A
Name	Fc fragment of IgG, high affinity Ia, receptor (CD64)
Aliases	CD64; CD64A; Fc fragment of IgG, high affinity Ia, receptor for (CD64); FCRI; Fc gamma receptor; Fc-gamma RI ......
Chromosomal Location	1q21.2-q21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of FCGR1A in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.466	0.247
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.854	0.385
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.184	0.82
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.586	0.238
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.447	0.739
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.77	0.668
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.015	0.975
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.218	0.864
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.266	0.848
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.933	0.589
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.967	0.726
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.392	0.104

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of FCGR1A in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	2.7	1	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	3.4	0.3	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	14.3	0	14.3	0.238
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	15.4	0	15.4	0.482
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	3.7	-3.7	0.415
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	7.7	-7.7	0.371
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	FCGR1A
Name	Fc fragment of IgG, high affinity Ia, receptor (CD64)
Aliases	CD64; CD64A; Fc fragment of IgG, high affinity Ia, receptor for (CD64); FCRI; Fc gamma receptor; Fc-gamma RI ......
Chromosomal Location	1q21.2-q21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FCGR1A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	FCGR1A
Name	Fc fragment of IgG, high affinity Ia, receptor (CD64)
Aliases	CD64; CD64A; Fc fragment of IgG, high affinity Ia, receptor for (CD64); FCRI; Fc gamma receptor; Fc-gamma RI ......
Chromosomal Location	1q21.2-q21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FCGR1A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FCGR1A. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	FCGR1A
Name	Fc fragment of IgG, high affinity Ia, receptor (CD64)
Aliases	CD64; CD64A; Fc fragment of IgG, high affinity Ia, receptor for (CD64); FCRI; Fc gamma receptor; Fc-gamma RI ......
Chromosomal Location	1q21.2-q21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FCGR1A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	FCGR1A
Name	Fc fragment of IgG, high affinity Ia, receptor (CD64)
Aliases	CD64; CD64A; Fc fragment of IgG, high affinity Ia, receptor for (CD64); FCRI; Fc gamma receptor; Fc-gamma RI ......
Chromosomal Location	1q21.2-q21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of FCGR1A expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	FCGR1A
Name	Fc fragment of IgG, high affinity Ia, receptor (CD64)
Aliases	CD64; CD64A; Fc fragment of IgG, high affinity Ia, receptor for (CD64); FCRI; Fc gamma receptor; Fc-gamma RI ......
Chromosomal Location	1q21.2-q21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between FCGR1A and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	FCGR1A
Name	Fc fragment of IgG, high affinity Ia, receptor (CD64)
Aliases	CD64; CD64A; Fc fragment of IgG, high affinity Ia, receptor for (CD64); FCRI; Fc gamma receptor; Fc-gamma RI ......
Chromosomal Location	1q21.2-q21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting FCGR1A collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting FCGR1A.

ID	Name	Drug Type	Targets	#Targets
DB00002	Cetuximab	Biotech	C1QA, C1QB, C1QC, C1R, C1S, EGFR, FCGR1A, FCGR2A, FCGR2B, FCGR2C, ......	12
DB00005	Etanercept	Biotech	C1QA, C1QB, C1QC, C1R, C1S, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A ......	14
DB00028	Immune Globulin Human	Biotech	C3, C4A, C4B, C5, FCGR1A, FCGR1B, FCGR2A, FCGR2B, FCGR2C, FCGR3A, ......	11
DB00051	Adalimumab	Biotech	C1QA, C1QB, C1QC, C1R, C1S, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A ......	12
DB00054	Abciximab	Biotech	C1QA, C1QB, C1QC, C1R, C1S, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A ......	14
DB00056	Gemtuzumab ozogamicin	Biotech	C1QA, C1QB, C1QC, C1R, C1S, CD33, FCGR1A, FCGR2A, FCGR2B, FCGR2C, ......	12
DB00072	Trastuzumab	Biotech	C1QA, C1QB, C1QC, C1R, C1S, EGFR, ERBB2, FCGR1A, FCGR2A, FCGR2B, F ......	13
DB00073	Rituximab	Biotech	C1QA, C1QB, C1QC, C1R, C1S, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A ......	12
DB00074	Basiliximab	Biotech	C1QA, C1QB, C1QC, C1R, C1S, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A ......	13
DB00075	Muromonab	Biotech	C1QA, C1QB, C1QC, C1R, C1S, CD247, CD3D, CD3E, CD3G, FCGR1A, FCGR2 ......	15
DB00078	Ibritumomab tiuxetan	Biotech	C1QA, C1QB, C1QC, C1R, C1S, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A ......	12
DB00081	Tositumomab	Biotech	C1QA, C1QB, C1QC, C1R, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A, FCG ......	11
DB00087	Alemtuzumab	Biotech	C1QA, C1QB, C1QC, C1R, CD52, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3 ......	11
DB00092	Alefacept	Biotech	C1QA, C1QB, C1QC, C1R, CD2, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A ......	11
DB00095	Efalizumab	Biotech	C1QA, C1QB, C1QC, C1R, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A, FCG ......	11
DB00108	Natalizumab	Biotech	C1QA, C1QB, C1QC, C1R, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A, FCG ......	12
DB00110	Palivizumab	Biotech	C1QA, C1QB, C1QC, C1R, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A, FCG ......	10
DB00111	Daclizumab	Biotech	C1QA, C1QB, C1QC, C1R, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A, FCG ......	12
DB00112	Bevacizumab	Biotech	C1QA, C1QB, C1QC, C1R, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A, FCG ......	11
DB00707	Porfimer sodium	Small Molecule	FCGR1A, LDLR	2
DB00992	Methyl aminolevulinate	Small Molecule	FCGR1A	1
DB06607	Catumaxomab	Biotech	CD3E, EPCAM, FCGR1A, FCGR2A, FCGR3A, FCGR3B	6
DB11767	Sarilumab	Biotech	FCGR1A, FCGR2A, FCGR2B, FCGR3A, FCGR3B, IL6R	6

Browse FCGR1A